Loading stock data…
ABUS
$4.32+0.12 (+2.86%)
Market ClosedLast close May 1
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arbutus Biopharma Corporation in the Healthcare sector is trading at $4.32. The stock is currently 15% below its 52-week high of $5.10, remaining 1.6% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why ABUS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.32
Potential Upside
5%
Whystock Fair Value$4.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$872.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.75%
Volume
Today's trading volume
922,025
Recent News
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Moderna Q1 2026 earnings beat on international COVID vaccine sales
The company posted $389 million in first-quarter revenue, well above analyst expectations, with 80% coming from international markets
Moderna sees revenue bump from international COVID vaccine sales
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
Moderna Reports Higher Revenue but Posts a Loss
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.